Clinical Trials Logo

Cutaneous T-Cell Lymphoma clinical trials

View clinical trials related to Cutaneous T-Cell Lymphoma.

Filter by:

NCT ID: NCT00274651 Terminated - Clinical trials for Non-Hodgkin's Lymphoma

A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas

PXD101-CLN-6
Start date: January 2006
Phase: Phase 2
Study type: Interventional

Open-label, non-randomized trial to assess the effectiveness of PXD101 in patients with recurrent or refractory cutaneous or peripheral and other types of T-cell lymphomas. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Patients are treated with belinostat(PXD101) 1000 mg/m2 on days 1-5 of a 21 day cycle.